Description
Trade name:
Brilique
Compound:
Each tablet contains:
Ticagrelor 90 mg.
Auxiliary components:
mannitol, calcium hydrogen phosphate, sodium carboxymethyl starch, hyprolose, magnesium stearate.
Properties:
Brilik contains ticagrelor, a member of the cyclopentyltriazolopyrimidine chemical class, which is a selective and reversible direct-acting P2Y12 receptor antagonist that prevents ADP-mediated P2Y12-dependent platelet activation and aggregation. Ticagrelor does not prevent ADP binding, but its interaction with the platelet P2Y12 receptor prevents ADP-induced signal transduction. Because platelets are involved in the initiation and/or progression of thrombotic complications of atherosclerosis, inhibition of platelet function has been shown to reduce the risk of cardiovascular events such as death, myocardial infarction, or stroke.
Ticagrelor has an additional mechanism of action by increasing local concentrations of endogenous adenosine by inhibiting the endogenous nucleoside transporter 1 (ENT-1).
Adenosine is formed locally at sites of hypoxia and tissue damage by release from ATP and ADP. Ticagrelor inhibits ENT-1 and prolongs the T1/2 of adenosine, thereby increasing its local extracellular concentration, enhancing the local adenosine response. Ticagrelor has no clinically significant direct effect on adenosine receptors (A1, A2A, A2B, A3) and is not metabolized to adenosine. Adenosine has the following effects, which include: vasodilation, cardioprotection, inhibition of platelet aggregation, modulation of inflammation and the occurrence of dyspnea, which may affect the clinical profile of ticagrelor. In healthy volunteers and in patients with acute coronary syndrome (ACS), ticagrelor has been shown to potentiate the following effects of adenosine: vasodilation (measured as increased coronary blood flow in healthy volunteers; headache), inhibition of platelet function (in vitro in human whole blood), and dyspnea. However, an association of elevated local adenosine concentrations with clinical outcomes (morbidity and mortality) has not been demonstrated.
Indications:
In combination with acetylsalicylic acid:
– for the prevention of atherothrombotic complications in patients with acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction [STEMI]), including patients receiving drug therapy and patients undergoing percutaneous coronary intervention or coronary artery bypass grafting.
Method of administration and dosage:
Take the drug after consultation with your doctor.
Initial dose:
2 tablets (180 mg) per day, at the same time.
Afterwards take 1 tablet 2 times a day. The course of treatment is 12 months.
Take at the same time in the morning and evening.
Contraindications:
– hypersensitivity to ticagrelor or any of the components of the drug;
– active pathological bleeding;
– history of intracranial hemorrhage;
– moderate or severe liver failure;
– concomitant use of ticagrelor with strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir);
– children and adolescents under 18 years of age (due to the lack of data on the efficacy and safety of use in this group of patients).
Precautions:
In patients with acute coronary syndrome treated with Brilic and aspirin, there was an increased risk of non-CABG-related major bleeding and bleeding requiring increased medical attention, such as major + minor bleeding according to the PLATO definition, but no increased risk of fatal/life-threatening bleeding.
When prescribing Brilicu, the benefit of preventing atherothrombotic events should be weighed against the risk in patients at increased risk of bleeding.
Side effects:
Nervous system, psyche and sensory organs: confusion, dizziness, fainting, headache, intracranial hemorrhage, anxiety, insomnia.
Cardiovascular system, blood (hemostasis, hematopoiesis) and lymphatic system: arterial hypotension, tachycardia, arterial hypertension, bradycardia, chest pain, heart rhythm disturbances.
Digestive system: gastrointestinal bleeding (including bleeding from the gums, rectal bleeding, bleeding from gastric ulcers), diarrhea, nausea, dyspepsia, constipation.
Storage method:
At a temperature not exceeding 30 degrees. In a dry place.
